Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Study Details
Study Description
Brief Summary
Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value <0.05 as significant, was used.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Group A applied Clobetasol Propionate 0.05% Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months. |
Drug: Group A applied topical Clobetasol Propionate
Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
|
Active Comparator: Group B applied topical Tacrolimus 0.1% Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. |
Drug: Group B applied topical Tacrolimus
Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
|
Outcome Measures
Primary Outcome Measures
- The degree of response was assessed on The basis of hair regrowth as excellent, marked, moderate or slight. [6 months]
The degree of response was assessed on the basis of hair regrowth as excellent (>75% regrowth), marked (51-75% regrowth), moderate (26-50% regrowth), or slight (≤25% regrowth)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients age 20 to 50 years
-
Both male and female
-
Duration of illness less than 2 months
-
those who never received any treatment before
Exclusion Criteria:
-
Patients having duration of alopecia greater than 2 months
-
Atypical alopecia areata i.e., Alopecia universalis etc
-
Hypersensitivity history to topical corticosteroids or tacrolimus
-
patients taking any systemic immune suppression
-
pregnancy/lactation
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Danyal Sajjad | Abbottabad | Khyber Pakhtunkhwa | Pakistan |
Sponsors and Collaborators
- Combined Military Hospital Abbottabad
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CMHAbbottabad2021